Obexelimab

The IgG4-related disease market is expected to grow significantly by 2034, driven by increasing prevalence and awareness. Current treatments rely on off-label therapies, with emerging drugs like obexelimab and inebilizumab poised to revolutionize treatment. The US leads the market, with key players including Zenas BioPharma and Horizon Therapeutics.

The IgG4-related disease treatment market is set to grow significantly by 2034, driven by increasing prevalence, awareness, and the launch of new therapies. Current treatments rely on off-label drugs like glucocorticoids and rituximab, with no approved therapies specifically for IgG4-RD. Key players like Zenas BioPharma and Horizon Therapeutics are advancing treatments, with promising pipeline drugs expected to revolutionize the market. The 7MM market size was around USD 150 million in 2023, with the US leading. The disease, affecting mainly middle-aged to elderly men, presents challenges in diagnosis and treatment, emphasizing the need for early intervention to prevent organ damage.

The IgG4-related disease market, involving companies like Zenas BioPharma and Sanofi, is projected to grow significantly by 2034, driven by increasing prevalence and awareness. Current treatments rely on off-label therapies, with emerging drugs like obexelimab and inebilizumab expected to revolutionize treatment patterns. The US leads the market, with a focus on addressing unmet medical needs and improving patient outcomes.

The Global Antibody Therapy Market is projected to grow from US$ 231.6 billion in 2023 to US$ 669.1 billion by 2033, driven by technological advancements, regulatory approvals, and increasing demand for innovative treatments in chronic diseases, oncology, and autoimmune disorders.

Zenas BioPharma completes targeted enrollment for Phase 3 INDIGO trial of obexelimab in IgG4-RD, largest trial for the condition, with topline results expected by end of 2025.

Multiple sclerosis (MS) is a chronic CNS disease with varied symptoms, caused by immune system attacks on myelin. Biotech companies like Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma are developing new treatments, including BTK inhibitors, CAR-T therapies, and bispecific antibodies. The global MS drug market is expected to grow significantly, offering hope for more effective treatments for different forms of MS.

Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.

IgG4-RD treatment necessity varies by organ involvement and risk. Glucocorticoids are primary for remission, with maintenance for relapse risks. Biological agents like rituximab show efficacy. Surgical options are for specific cases. Treatment strategies consider disease severity, comorbidities, and relapse risks.

IgG4-RD is a fibroinflammatory disease affecting multiple organs, with B and T cells playing key roles in its pathogenesis. Diagnosis requires clinicopathological correlation due to the lack of specific tests. Glucocorticoids are effective but limited by toxicity, prompting research into glucocorticoid-sparing agents. B cell-targeted therapies like rituximab show promise, though more randomized trials are needed. Untreated IgG4-RD can lead to irreversible organ damage, emphasizing the need for close monitoring and long-term immunosuppression in some cases.